Neurology Central

Are soluble APP-α and APP-β in CSF valuable for earlier diagnosis of dementia disorders?


sAPPα and sAPPβ as potential biomarkers of dementia disorders

Alzheimer’s disease (AD), characterized by the cerebral accumulation of the well-known pathological hallmark proteins, amyloid β-protein (Aβ) and phosphorylated tau (p-tau) protein, is the most prevalent dementia disorder. Recent studies have revealed that Aβ deposition gradually progresses during a long asymptomatic period that precedes the onset of mild cognitive impairment (MCI) due to AD (MCI-AD); this phase is now called preclinical AD [1]. Thus, the brain pathology evidently develops at the MCI-AD stage. Taking into account such characteristic features of disease progression, it becomes increasingly critical to accurately diagnose dementia disorders at earlier stages to enable appropriate interventions.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.